Evidence map›Paper›PMID 25743327›Full record

ArticleAnnals of surgical oncology2015

Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions.

Sean P Dineen, Christina L Roland, Rachel Feig, Caitlin May, Shouhao Zhou, Elizabeth Demicco, Ghadah Al Sannaa, Davis Ingram, Wei-Lein Wang, Vinod Ravi and 8 more

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  13. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Sean P DineenDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Christina L RolandDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Rachel FeigDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Caitlin MayDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Shouhao ZhouDepartment of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth DemiccoDepartment of Pathology, Mount Sinai Hospital, New York, NY, USA.
Ghadah Al SannaaDepartment of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
Davis IngramDepartment of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
Wei-Lein WangDepartment of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
Vinod RaviDepartment of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Ashleigh GuadagnoloDepartment of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Dina LevDeparment of Surgery, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Raphael E PollockDepartment of Surgery, The Ohio State University, Columbus, OH, USA.
Kelly HuntDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Janice CormierDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Alex LazarDepartment of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.
Barry FeigDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Keila E TorresDepartment of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. ketorres@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USMount Sinai Hospital · USSheba Medical Center · ILThe Ohio State University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Axl receptor signaling in MPNST; potential node for therapyK08CA160443 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TORRES, KEILA ENITT · 2012 to 2016
$853k
NCI NIH HHS 2P30CA016672-38NCI NIH HHS K08 CA160443NCI NIH HHS K08CA160443NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundRadiation therapy is used increasingly as a component of multidisciplinary treatment for many solid tumors. One complication of such treatment is the development of radiation-associated sarcoma (RAS). Undifferentiated pleomorphic sarcoma (UPS), previously termed "malignant fibrous histiocytoma" (MFH) is the most common histologic subtype of RAS. This study investigated the clinical outcomes for patients with radiation-associated UPS (RA-UPS/MFH).

methodsThe study identified 1068 patients with UPS/MFH treated at the authors' institution. Patient and tumor factors were collected and compared. Regression analysis was performed to identify independent predictors of survival. A matched-cohort survival and recurrence analysis was performed for radiation-associated and sporadic UPS/MFH.

resultsThe findings showed that RA-UPS/MFH comprised 5.1 % of the UPS population. The median latency to the development of RA-UPS/MFH was 9.3 years. The 5-year disease-specific survival (DSS) was 52.2 % for patients identified with RA-UPS/MFH (n = 55) compared with 76.4 % for patients with unmatched sporadic UPS/MFH (n = 1,013; p < 0.001). A matched-cohort analysis also demonstrated that the 5-year DSS was significantly worse for RA-UPS/MFH (52.2 vs 73.4 %; p = 0.002). Furthermore, higher local recurrence rates were observed for patients with RA-UPS/MFH than for patients with sporadic lesions (54.5 vs 23.5 %; p < 0.001). Radiation-associated status and incomplete resection were identified as independent predictors of local recurrence.

conclusionThis study demonstrated worse clinical outcomes for patients with RA-UPS/MFH than for patients with sporadic UPS/MFH. Local recurrence was significantly higher for patients with RA-UPS/MFH, suggesting a unique tumor biology for this challenging disease.

Indexed as

AdolescentAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHistiocytoma, Malignant FibrousHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm, ResidualNeoplasms, Radiation-InducedProportional Hazards Models

Identifiers

PMID25743327
PMCPMC4561200
OpenAlexW2092713768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.